

# MASTER TRIAL LIST

JANUARY 2025

**SCHEMAS ARE INACTIVE**



New or ReOpened Trials



No Trials Currently Available

**JUST IN TIME TRIALS (JIT)**

AML	ANAL	ALL
APL	BILIARY	BLADDER-UROTHELIAL
BRAIN	BREAST/ GYN	CANCER CONTROL / SURVIVORSHIP
CLL	CML	COLON-RECTAL
ESOPHAGEAL - GASTRIC	HEAD & NECK	LYMPHOMA
MDS/MPN	MELANOMA	MERKEL
MOLECULAR STUDIES	MULTIPLE MYELOMA	NEUROENDOCRINE
NSCLC	PANCREATIC	PROSTATE
RADIATION TRIALS	RENAL CELL	SARCOMA
SMALL CELL LUNG CANCER		

Updated 1.13.25

**RADIATION LOCATIONS:**

- OSF Glen Oak - OSF main hospital
- OSF Route 91 (attached to Illinois CancerCare)
- SJMC - St Joseph Medical Center



**JUST IN TIME (JIT) TRIALS**

\*Contact Disease Specific Navigator

**Multi-Disease Site: Advanced/Metastatic Solid Tumors**

**EAY191- (Combomatch) E5**

A Randomized Phase II Study of AMG 510 (Sotorasib) With or Without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment Trial

**EAY191 - (Combomatch) N5**

A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination With Palbociclib, a CDK4/6 Inhibitor, in Patients With HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment Trial

**EAY191 (Combomatch) - S3**

A Phase II Study of Paclitaxel + Ipatasertib In Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors)

**RAIN-3202**

A Phase 2 Basket Study of Milademetan in Advanced/Metastatic Solid Tumors

**ALL**

**EA9213**

A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia (T-ALL)

**AL Amyloidosis**

**S2213**

A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients With Newly Diagnosed AL Amyloidosis

**Biliary**

**EAY191 (ComboMatch) -A6**

FOLFOX in Combination With Binimetinib as 2nd Line Therapy for Patients With Advanced Biliary Tract Cancers With MAPK Pathway Alterations: A ComboMATCH Treatment Trial

**Breast**

**EAY191 (Combomatch) - N2**

*Molecular Analysis for combination Therapy Choice* (**SUBSTUDY- N2**: Phase II Trial of Fulvestrant and Binimetinib in Patients With Hormone Receptor-Positive Metastatic Breast Cancer With A Frameshift or Nonsense Mutation or Genomic Deletion in NF1)

**CLL**

<a href="#"><u>S1925</u></a>	Randomized, Phase III Study of Early Intervention With Venetoclax and Obinutuzumab Versus Delayed Therapy With Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study
<b>Gynecological</b>	
<a href="#"><u>GY026</u></a>	A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-Oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma <i>(temporarily closed for stage I-II for interim analysis)</i>
<b>Genitourinary - Rare</b>	
<a href="#"><u>A031702</u></a>	Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors <i>Enrolling cohorts: renal collecting duct, bladder plasmacytoid, sarcomatoid bladder, urethral carcinoma (which allows any histology urothelial, squamous, clear cell, or adenocarcinoma), and Bone only (which allows for any GU histology, except prostate).</i>
<b>Head &amp; Neck</b>	
<a href="#"><u>A092205</u></a>	<b>NEW!</b> Randomized Phase III Trial of Pembrolizumab vs. Pembrolizumab/Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma With Platinum Refractory Disease
<a href="#"><u>EA3191</u></a>	A Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features
<a href="#"><u>EA3202</u></a>	<b>NEW!</b> A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers
<a href="#"><u>EA3211</u></a>	Phase III Randomized Trial of Immunotherapy With or Without Consolidative Radiotherapy for Oligometastatic Head and Neck Squamous Cell Carcinoma
<a href="#"><u>HN010</u></a>	A Controlled, Randomized Phase II Trial of Docetaxel Plus Trastuzumab Versus Ado-Trastuzumab Emtansine for Recurrent, Metastatic, or Treatment-Naive, Unresectable HER2-Positive Salivary Gland Cancer
<b>Melanoma</b>	
<a href="#"><u>A091903</u></a>	A Randomized Phase II Trial of Adjuvant Nivolumab With or Without Cabozantinib in Patients With Resected Mucosal Melanoma

## Multiple Myeloma

[A062102](#)

SCHEMA

Randomized Phase 2 Study of Ibrdomide Maintenance Therapy Following Idecaptagene Vicleucel CAR-T in Multiple Myeloma Patients

[EAA173](#)

SCHEMA

Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)

[S2209](#)

SCHEMA

A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance

## Neuroendocrine

[S2104](#)

Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors

## Pancreas

[A022106](#)

Phase II/III Second-Line NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM)

[S2104](#)

Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors

## Rectal

[EA2201](#)

**Temporarily Closed (RT at Glen Oak, UPHM)** A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma

## Thyroid

[EA3231](#)

A Randomized Phase III Study of BRAF-Targeted Therapy vs Cabozantinib in RAI-Refractory Differentiated Thyroid Cancer with BRAF V600Em



# MASTER TRIAL LIST

JANUARY 2025



## AML

Navigator - Heather x3661

MM1YA-S01

SCHEMA

A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7 + 3) to (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, and Azacitidine + Venetoclax in Patients Aged 59 or Younger With High-Risk (Adverse) Acute Myeloid Leukemia; **A MYELOMATCH Clinical Trial**



ILLINOIS  
CANCERCARE, P.C.

*Specializing in Cancer and Blood Disorders*

# MASTER TRIAL LIST

JANUARY 2025



**MENU**

*ANAL*

**Navigator - Carrie x3621**



ILLINOIS  
CANCERCARE, P.C.

*Specializing in Cancer and Blood Disorders*

# MASTER TRIAL LIST

JANUARY 2025

[MENU](#)

*APL*

Navigator - Heather x3661

*There are no trials available at this time*



# MASTER TRIAL LIST

JANUARY 2025



## ACUTE LYMPHOBLASTIC LEUKEMIA

Navigator - Heather x3661

[EA9213 - JIT Trial](#)

A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia (T-ALL)





# MASTER TRIAL LIST

JANUARY 2025



## BILIARY

Navigator - Carrie x3621

<p><a href="#">EAY191 (ComboMatch) -A3</a></p> <p><a href="#">SCHEMA</a></p>	<p>Palbociclib and Binimetinib in RAS-Mutant Cancers: A ComboMATCH Treatment Trial (<i>cohorts for pancreatic cancer and other RAS mutant tumors are temporarily closed</i>)</p>
<p><a href="#">EAY191 (ComboMatch) -A6</a></p> <p><a href="#">(JIT)</a></p>	<p>FOLFOX in Combination With Binimetinib as 2nd Line Therapy for Patients With Advanced Biliary Tract Cancers With MAPK Pathway Alterations: A ComboMATCH Treatment Trial</p>



# MASTER TRIAL LIST

JANUARY 2025



## BLADDER / UROTHELIAL

Navigator - Carrie x3621

### ADJUVANT / NEOADJUVANT

**A032103**

SCHEMA

An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer (MODERN)

### METASTATIC

*no trial available at this time*



# MASTER TRIAL LIST

JANUARY 2025

MENU

## BRAIN

Navigator - Carrie x3621

<p><a href="#"><u>A071702</u></a></p> <p>SCHEMA</p>	<p><b>Temporarily Suspended</b> A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma</p>
<p><a href="#"><u>A072201</u></a></p> <p>SCHEMA</p>	<p><b>Temporarily Suspended</b> Randomized Phase II Trial of Anti-Lag-3 and Anti-PD-1 Blockade vs. SOC in Patients With Recurrent Glioblastoma</p>
<p><a href="#"><u>BN011</u></a></p> <p>SCHEMA</p>	<p><b>(RT at SJMC, Glen Oak)</b> A Phase III Trial of Gleostine® (Lomustine)-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients With Methylated MGMT Promoter Glioblastoma</p>



**BREAST**

Navigator - Angie x3613

**DCIS**

No trials at this time

**NEO/ADJUVANT TREATMENT**

S1706\*

**Not Actively Screening - Contact Navigator** - A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer (All biomarker subgroups eligible) | \*JIT TRIAL - expect 1 week delay to consent pt

**Neo/Adjuvant - HER2 Positive**

A011801

The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib

**Neo/Adjuvant - Hormone Receptor Positive / HER2 Negative**

BR007

SCHEMA

(RT at Glen Oak, Rt 91, SJMC) Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer

BR009

SCHEMA

A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET)

J2J-MC-JZLH / EMBER-4

SCHEMA

(Peoria, Bloomington, Galesburg, Pekin, Washington, Ottawa, Peru) A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence

S2206

SCHEMA

Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone for MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer

**Neo/Adjuvant - Triple Negative**

A012103

SCHEMA

OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy

<u>01-PS-001/ NeXT</u> 	(sites TBD) Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I)
<u>S2212 / SCARLET</u> 	Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study
<b>METASTATIC TREATMENT</b>	
<b>Metastatic - HER2 Positive</b> <i>(no trials at this time)</i>	
<b>Metastatic - Hormone Receptor Positive / HER2 Negative</b>	
<u>EAY191</u> <u>(Combomatch) - N2</u> <u>(JIT)</u>	<i>Molecular Analysis for combination Therapy Choice</i> ( <b>SUBSTUDY- N2</b> : Phase II Trial of Fulvestrant and Binimetinib in Patients With Hormone Receptor-Positive Metastatic Breast Cancer With A Frameshift or Nonsense Mutation or Genomic Deletion in NF1)
<u>S1703</u>	Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients with Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer
<u>S2007</u>	<u>Not Actively Screening - contact Navigator-</u> A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients With HER2-Negative Breast Cancer and Brain Metastases
<b>Metastatic - Triple Negative</b> <i>(no trials at this time)</i>	
<b>SURGERY / RADIATION ONLY</b>	
<u>MA.39</u>	Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer <i>(RT: Glen Oak)</i>
<b>CANCER CONTROL (Breast only)</b>	
<u>CC011</u> 	Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors: A Multi-Center Randomized Double-Blinded Controlled Trial
<u>EAQ202</u>	Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials <i>(caucasian cohort is closed - currently enrolling only non-caucasian participants)</i>
<u>EAQ222CD</u> 	<b>Coming Soon!</b> Effectiveness of Out-of-Pocket Cost COMMunication and Financial Navigation (CostCOM) in Cancer Patients
<u>S2010</u> 	<b>Closing 1.15.25</b> A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone to Improve Persistence With Endocrine Therapy in Young Women With Stage I-III Breast Cancer (ASPEN)

<p><b><u>S2013</u></b></p> <p>SCHEMA</p>	<p>(Peoria, Bloomington, Galesburg, Pekin, Washington) Immune Checkpoint Inhibitor Toxicity: A Prospective Observational Study (I-CHECKIT) <b>(Enrolling to Cohort 2 only: ICI-chemo regimens for NSCLC, SCLC, TNBC, and Gastroesophageal)</b></p>
<p><b><u>URCC-18007</u></b></p>	<p>Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue- <i>at least 2 months out from surgery/tx/radiation</i></p>
<p><b><u>URCC 19185</u></b></p> <p>SCHEMA</p>	<p>(Peoria, Bloomington, Canton, Galesburg, Ottawa, Pekin, Peru, Washington) Multicenter Randomized Controlled Trial Comparing Brief Behavioral Therapy for Cancer Related Insomnia (BBT-CI) and Healthy Eating Education Learning (HEAL)</p>
<p><b><u>URCC 21038</u></b></p> <p>SCHEMA</p>	<p>(Peoria, Bloomington, Galesburg, Pekin, Washington) Disparities in Results of ImmuneCheckpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated With anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting <i>(limited enrollment remaining for caucasian pts - contact CRC to confirm availability)</i></p>
<p><b><u>WF-1901</u></b></p> <p>SCHEMA</p>	<p>Internet-delivered Management of Pain Among Cancer Treatment Survivors (IMPACTS)</p>
<p><b><u>WF-2202</u></b></p> <p>SCHEMA</p>	<p>Optimizing Psychosocial Intervention for Breast Cancer-Related Sexual Morbidity:The Sexual Health and Intimacy Education (SHINE) Trial <b><i>(temporarily closing to non-hispanic white participants on 8.22.24)</i></b></p>
<p><b>GYNECOLOGICAL</b></p>	
<p>Navigator - Angie x3613</p>	
<p><b><u>NRG - GY023</u></b></p> <p>SCHEMA</p>	<p><b>Temporarily Closed</b> A Randomized Phase II Trial of Triplet Therapy (a PD-L1 Inhibitor (Durvalumab) MEDI4736 in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or (Durvalumab) MEDI4736 and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab</p>
<p><b><u>EAY191 (ComboMATCH) - A3</u></b></p> <p>SCHEMA</p>	<p>Palbociclib and Binimetinib in RAS-Mutant Cancers: A ComboMATCH Treatment Trial <i>(cohort for pancreatic cancer temporarily closed)</i></p>
<p><b><u>EAY191 (ComboMATCH) - N4</u></b></p>	<p><i>Molecular Analysis for combination Therapy Choice</i> <b>(SUBSTUDY- N4:</b> A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers)</p>



## CANCER CONTROL

### SURVIVORSHIP

<a href="#"><u>CC011</u></a> SCHEMA	Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors: A Multi-Center Randomized Double-Blinded Controlled Trial
<a href="#"><u>EAQ211</u></a> SCHEMA	Social Genomic Mechanisms of Health Disparities Among Adolescent and Young Adult (AYA) Survivors of Hodgkin and Non-Hodgkin Lymphoma
<a href="#"><u>URCC-18007</u></a>	Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue - <i>at least 2 months out from surgery/tx/radiation</i>
<a href="#"><u>WF-1901</u></a> SCHEMA	Internet-delivered Management of Pain Among Cancer Treatment Survivors (IMPACTS)
<a href="#"><u>WF-2202</u></a> SCHEMA	Optimizing Psychosocial Intervention for Breast Cancer-Related Sexual Morbidity: The Sexual Health and Intimacy Education (SHINE) Trial <i>(temporarily closing to non-hispanic white participants on 8.22.24)</i>

### MULTI-DISEASE SITES

<a href="#"><u>EAQ202</u></a> SCHEMA	Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials <i>(caucasian cohort is closed - currently enrolling only non-caucasian participants)</i>
<a href="#"><u>EAQ222CD</u></a> SCHEMA	<b>Coming Soon!</b> Effectiveness of Out-of-Pocket Cost COMMunication and Financial Navigation (CostCOM) in Cancer Patients
<a href="#"><u>S2013</u></a> SCHEMA	<b>(Peoria, Bloomington, Galesburg, Pekin, Washington)</b> Immune Checkpoint Inhibitor Toxicity: A Prospective Observational Study (I-CHECKIT) <i>(Enrolling to Cohort 2 only: ICI - chemo regimens for NSCLC, SCLC, TNBC, and Gastroesophageal)</i>
<a href="#"><u>URCC-18007</u></a>	Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue - <i>at least 2 months out from surgery/tx/radiation</i>
<a href="#"><u>URCC 19185</u></a> SCHEMA	<b>(Peoria, Bloomington, Canton, Galesburg, Ottawa, Pekin, Peru, Washington)</b> Multicenter Randomized Controlled Trial Comparing Brief Behavioral Therapy for Cancer Related Insomnia (BBT-CI) and Healthy Eating Education Learning (HEAL)
<a href="#"><u>URCC 21038</u></a> SCHEMA	<b>(Peoria, Bloomington, Galesburg, Pekin, Washington)</b> Disparities in Results of ImmuneCheckpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated With anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting <i>(limited enrollment remaining for caucasian pts - contact CRC to confirm availability)</i>
<a href="#"><u>URCC 22063</u></a> SCHEMA	Longitudinal Observational Trial to Uncover Subtypes of Cancer Cachexia
<a href="#"><u>WF-1901</u></a> SCHEMA	Internet-delivered Management of Pain Among Cancer Treatment Survivors (IMPACTS)

### BREAST

<u>CC011</u> <small>SCHEMA</small>	Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors: A Multi-Center Randomized Double-Blinded Controlled Trial
<u>S2010</u> <small>SCHEMA</small>	<b>Closing 1.15.25</b> A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone to Improve Persistence With Endocrine Therapy in Young Women With Stage I-III Breast Cancer (ASPEN)
<u>WF-2202</u> <small>SCHEMA</small>	Optimizing Psychosocial Intervention for Breast Cancer-Related Sexual Morbidity: The Sexual Health and Intimacy Education (SHINE) Trial <i>(temporarily closing to non-hispanic white participants on 8.22.24)</i>
<b>COLORECTAL</b>	
<u>WF-1806</u> <small>SCHEMA</small>	Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer: The M&M Study
<b>LYMPHOMA</b>	
<u>EAQ211</u> <small>SCHEMA</small>	Social Genomic Mechanisms of Health Disparities Among Adolescent and Young Adult (AYA) Survivors of Hodgkin and Non-Hodgkin Lymphoma
<b>REGISTRY</b>	
*Contact Disease Specific Navigator	
<u>PRECEDE</u>	The Pancreatic Cancer Early Detection Consortium
<u>TP-CA-007 ARIES</u>	TEMPUS ARIES: A Biobank Registry Platform Study in Oncology <i>(currently enrolling KRAS+ CRC, NSCLC, and Pancreatic cancer pts)</i>



# MASTER TRIAL LIST

JANUARY 2025

MENU

CLL

Navigator - Heather x3661

## 1st Line

[S1925-JIT](#)

Randomized, Phase III Study of Early Intervention With Venetoclax and Obinutuzumab Versus Delayed Therapy With Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study

## 2nd Line, 3rd Line, etc.

[APG2575CG301](#)

SCHEMA

**(Peoria, Bloomington, Galesburg, Pekin, Peru, Ottawa, Washtington)** A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Lisoftoclax (APG-2575) in Previously Treated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (GLORA Study)

# MASTER TRIAL LIST

JANUARY 2025



*CML*

Navigator - Heather x3661

*no trials at this time*



# MASTER TRIAL LIST

JANUARY 2025








## COLON / RECTAL

Navigator - Carrie x3621

### Adjuvant

<p><u><a href="#">C-14</a></u></p>	<p>(Peoria, Bloomington, Canton, Galesburg, Ottawa, Pekin, Peru, Washington) Second Colorectal Cancer Clinical Validation Study to Predict Recurrence Using A Circulating Tumor DNA Assay To Detect Minimal Residual Disease (<b>CORRECT-MRD II</b>)</p>
<p><u><a href="#">EA2201 - JIT</a></u></p>	<p><b>Temporarily Closed (RT at Glen Oak)</b> A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma</p>
<p><u><a href="#">GI008</a></u></p> <p><small>SCHEMA</small></p>	<p>Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease</p>
<p><b>CANCER CONTROL (Colorectal only)</b></p>	
<p><u><a href="#">EAQ202</a></u></p> <p><small>SCHEMA</small></p>	<p>Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials (<i>caucasian cohort is closed - currently enrolling only <u>non</u>-caucasian participants</i>)</p>
<p><u><a href="#">EAQ222CD</a></u></p> <p><small>SCHEMA</small></p>	<p><b>COMING SOON!</b> Effectiveness of Out-of-Pocket Cost COMMunication and Financial Navigation (CostCOM) in Cancer Patients</p>
<p><u><a href="#">TP-CA-007 ARIES</a></u></p>	<p>TEMPUS ARIES: A Biobank Registry Platform Study in Oncology (<i>currently enrolling KRAS+ CRC, NSCLC, and Pancreatic cancer pts</i>)</p>
<p><u><a href="#">URCC-18007</a></u></p>	<p>Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue - <i>at least 2 months out from surgery/tx/radiation</i></p>

<p><b><u>URCC 19185</u></b></p> <p></p>	<p><b>(Peoria, Bloomington, Canton, Galesburg, Ottawa, Pekin, Peru, Washington)</b> Multicenter Randomized Controlled Trial Comparing Brief Behavioral Therapy for Cancer Related Insomnia (BBT-CI) and Healthy Eating Education Learning (HEAL)</p>
<p><b><u>URCC 21038</u></b></p> <p></p>	<p><b>(Peoria, Bloomington, Galesburg, Pekin, Washington)</b> Disparities in Results of ImmuneCheckpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated With anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting <i>(limited enrollment remaining for caucasian pts - contact CRC to confirm availability)</i></p>
<p><b><u>URCC 22063</u></b></p> <p></p>	<p>Longitudinal Observational Trial to Uncover Subtypes of Cancer Cachexia</p>
<p><b><u>WF-1806</u></b></p> <p></p>	<p>Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer: The M&amp;M Study</p>
<p><b><u>WF-1901</u></b></p> <p></p>	<p>Internet-delivered Management of Pain Among Cancer Treatment Survivors (IMPACTS)</p>



# MASTER TRIAL LIST

JANUARY 2025



## ESOPHAGEAL- GASTRIC


Navigator - Carrie x3621

<p><a href="#">A022102</a></p> <p><a href="#">SCHEMA</a></p>	<p>Randomized Phase III Trial of mFOLFIRINOX vs. FOLFOX With Nivolumab for First-Line Treatment of Metastatic HER2- Gastroesophageal Adenocarcinoma</p>
<p><a href="#">S2303</a></p> <p><a href="#">SCHEMA</a></p>	<p>Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab Versus Paclitaxel + Ramucirumab in Patients With PD-L1 CPS <math>\geq</math> 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMMUNE)</p>

## HEAD & NECK

Navigator - Ashton x3611

<p><a href="#"><u>A092205-JIT</u></a></p>	<p><b>NEW!</b> Randomized Phase III Trial of Pembrolizumab vs. Pembrolizumab/Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma With Platinum Refractory Disease</p>
<p><a href="#"><u>EA3161</u></a></p>	<p><b>Temporarily Closed   (RT at Glen Oak)</b> A Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC</p>
<p><a href="#"><u>EA3191 - JIT</u></a></p>	<p>A Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features</p>
<p><a href="#"><u>EA3202-JIT</u></a></p>	<p><b>NEW!</b> A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers</p>
<p><a href="#"><u>EA3211 - JIT</u></a></p>	<p>Phase III Randomized Trial of Immunotherapy With or Without Consolidative Radiotherapy for Oligometastatic Head and Neck Squamous Cell Carcinoma</p>
<p><a href="#"><u>HN009</u></a></p> <p><a href="#">SCHEMA</a></p>	<p><b>(RT at SJMC)</b> Randomized Phase II/III Trial of Radiation With High-Dose Cisplatin (100 mg/m<sup>2</sup>) Every Three Weeks Versus Radiation With Low-Dose Weekly Cisplatin (40 mg/m<sup>2</sup>) for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) (<b>accrual closed to p16+ oropharyngeal/unknown primary cohort</b>)</p>
<p><a href="#"><u>HN010 - JIT</u></a></p>	<p>A Controlled, Randomized Phase II Trial of Docetaxel Plus Trastuzumab Versus Ado-Trastuzumab Emtansine for Recurrent, Metastatic, or Treatment-Naive, Unresectable HER2-Positive Salivary Gland Cancer</p>

<p><a href="#"><u>S2101</u></a></p> <p></p>	<p><b>Temporarily Closed</b>   Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Patients With Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study</p>
<p><a href="#"><u>TP-CA-006 (PHOENIX)</u></a></p>	<p>A Longitudinal Multi-Omic Biomarker Profiling Study of Patients with Head &amp; Neck Squamous Cell Carcinoma (HNSCC)</p>

## LYMPHOMA

### HL

No HL trials at this time

### NHL

[GO44145](#)

SCHEMA

**(Peoria only)** | A Phase III, Multicenter, Randomized, Open-Label Study Comparing the Efficacy and Safety of Glofitamab (RO7082859) in Combination With Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

[M22-003](#)

SCHEMA

**Temporarily Closed (Peoria, Bloomington, Galesburg, Ottawa, Pekin, Peru, Washington)** A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) Compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2)

[S2308](#)

SCHEMA

Randomized Phase III Study of Mosunetuzumab vs Rituximab for Low Tumor Burden Follicular Lymphoma





ILLINOIS  
CANCERCARE, P.C.

*Specializing in Cancer and Blood Disorders*

# MASTER TRIAL LIST

JANUARY 2025



**MENU**

*MDS/MPN*

**Navigator - Heather x3661**

No trials at this time



# MASTER TRIAL LIST

JANUARY 2025



## MELANOMA

Navigator - Carrie x3621

<p><a href="#"><u>A091903 - JIT Trial</u></a></p>	<p>A Randomized Phase II Trial of Adjuvant Nivolumab With or Without Cabozantinib in Patients With Resected Mucosal Melanoma</p>
<p><a href="#"><u>R3767-ONC-22122</u></a></p> <p><a href="#">SCHEMA</a></p>	<p><b>(Peoria, Bloomington, Galesburg, Ottawa, Pekin, Peru, Washington)</b> A Phase 3 Study of Fixed Dose Combinations of Fianlimab and Cemiplimab Versus Relatlimab and Nivolumab in Participants with Unresectable or Metastatic Melanoma.</p>
<p><a href="#"><u>S2101</u></a></p> <p><a href="#">SCHEMA</a></p>	<p><b>Temporarily Closed</b>   Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Patients With Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study</p>



ILLINOIS  
CANCERCARE, P.C.  
*Specializing in Cancer and Blood Disorders;*

# MASTER TRIAL LIST

JANUARY 2025



**MENU**

**MERKEL**

**Navigator - Carrie x3621**

*no trials at this time.*

# MASTER TRIAL LIST

JANUARY 2025

MENU

## MOLECULAR STUDIES

[\\*Contact Disease Specific Navigator](#)

<a href="#">EAY191 - COMBOMATCH</a>	Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial ( <i>multiple substudies available</i> )
<a href="#">EAY191 (ComboMatch) -A3</a> <a href="#">SCHEMA</a>	Palbociclib and Binimetinib in RAS-Mutant Cancers: A ComboMATCH Treatment Trial ( <i>cohorts for pancreatic cancer and other RAS mutant tumors are temporarily closed</i> )
<a href="#">EAY191 (ComboMatch) -A6</a>	FOLFOX in Combination With Binimetinib as 2nd Line Therapy for Patients With Advanced Biliary Tract Cancers With MAPK Pathway Alterations: A ComboMATCH Treatment Trial
<a href="#">EAY191- (Combomatch) E5</a>	A Randomized Phase II Study of AMG 510 (Sotorasib) With or Without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment Trial
<a href="#">EAY191 (Combomatch) - N2</a>	<i>Molecular Analysis for combination Therapy Choice</i> ( <b>SUBSTUDY- N2</b> : Phase II Trial of Fulvestrant and Binimetinib in Patients With Hormone Receptor-Positive Metastatic Breast Cancer With A Frameshift or Nonsense Mutation or Genomic Deletion in NF1)
<a href="#">EAY191 (ComboMATCH) - N4</a>	<i>Molecular Analysis for combination Therapy Choice</i> ( <b>SUBSTUDY- N4</b> : A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers)
<a href="#">EAY191 - (Combomatch) N5</a>	A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination With Palbociclib, a CDK4/6 Inhibitor, in Patients With HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment Trial
<a href="#">EAY191 (Combomatch) - S3</a>	A Phase II Study of Paclitaxel + Ipatasertib In Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors)
<a href="#">PRECEDE</a>	The Pancreatic Cancer Early Detection Consortium
<a href="#">TP-CA-003 (Sculptor)</a>	<b>(Peoria, Blm, Canton, Gburg, Ottawa, Pekin, Peru, Washington)</b> A Tissue and Longitudinal Circulating Tumor DNA (ctDNA) Biomarker Profiling Study of Patients with Small Cell Lung Cancer (SCLC) Using Comprehensive Next-Generation Sequencing (NGS) Assays (TEMPUS)

<b><u>TP-CA-006 (PHOENIX)</u></b>	A Longitudinal Multi-Omic Biomarker Profiling Study of Patients with Head & Neck Squamous Cell Carcinoma (HNSCC)
<b><u>TP-CA-007 ARIES</u></b>	TEMPUS ARIES: A Biobank Registry Platform Study in Oncology ( <i>currently enrolling KRAS+ CRC, NSCLC, and Pancreatic cancer pts</i> )

# MASTER TRIAL LIST

JANUARY 2025



## ***MULTIPLE MYELOMA***

Navigator - Heather x3661

<p><b><u>A062102 - JIT</u></b> SCHEMA</p>	<p>Randomized Phase 2 Study of Iberdomide Maintenance Therapy Following Idecaptogene Vicleucel CAR-T in Multiple Myeloma Patients</p>
<p><b><u>EAA173 - JIT</u></b> SCHEMA</p>	<p>Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)</p>
<p><b><u>S2209 - JIT</u></b> SCHEMA</p>	<p>A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance</p>

# MASTER TRIAL LIST

JANUARY 2025

MENU

## NEUROENDOCRINE

Navigator - Carrie x3621

<a href="#"><u>A021804</u></a>	A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma
<a href="#"><u>S2104 - JIT Trial</u></a>	Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors

**ADJUVANT / NEOADJUVANT**

<p><a href="#">A081801</a> SCHEMA</p>	<p><b>(Peoria, Bloomington, Pekin, Galesburg, Washington, Ottawa)</b> Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)</p>
<p><a href="#">LU008</a> SCHEMA</p>	<p><b>(RT at Glen Oak, SJMC, Rt 91)</b> Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer</p>
<p><a href="#">CTIU2317-A082304-S2402</a> SCHEMA</p>	<p><b>NEW!</b> Perioperative Versus Adjuvant Systemic Therapy in Patients With Resectable Non-Small Cell Lung Cancer - PROSPECT LUNG</p>

**METASTATIC - 1st Line**

<p><a href="#">EA5182</a> SCHEMA</p>	<p>Randomized Phase III Study of Combination AZD9291 (osimertinib) and Bevacizumab versus AZD9291 (osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)</p>
<p><a href="#">MK-3475A-F84</a> SCHEMA</p>	<p><b>NEW!</b> A Phase 3 Randomized, Open-label Clinical Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK3475A) Versus Intravenous Pembrolizumab, in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS ≥50%</p>
<p><a href="#">SMT112-3003 (HARMONi-3)</a></p>	<p><b>COMING SOON!</b>   Phase 3 randomized, parallel-group, blinded, multiregional study comparing the efficacy and safety of ivonescimab or pembrolizumab, combined with carboplatin and paclitaxel or nab-paclitaxel for metastatic squamous NSCLC, or carboplatin plus pemetrexed chemotherapy for metastatic non-squamous NSCLC patients, who have not previously received systemic therapy for metastatic disease (HARMONi-3)</p>

**METASTATIC - 2nd/3rd Line**

<p><a href="#">LUNGMAP</a></p>	<p>A Master Protocol To Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated NSCLC.</p> <p>S1900G (substudy) - A Randomized Phase II Study of INC280 (Capmatinib) Plus Osimertinib With or Without Ramucirumab in Participants With EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer</p> <p>S1900J (substudy): A Phase II Study of Amivantamab SC (subcutaneous) in Participants with MET Amplification - Positive Stage IV or Recurrent NSCLC</p> <p>S1900K (substudy)- A Randomized Phase II Study of Tepotinib with or without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer</p>
--------------------------------	---

**CANCER CONTROL (NSCLC Only)**

<p><a href="#">EAQ202</a> SCHEMA</p>	<p>Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials (<i>caucasian cohort is closed - currently enrolling only non-caucasian participants</i>)</p>
<p><a href="#">EAQ222CD</a> SCHEMA</p>	<p><b>Coming Soon!</b> Effectiveness of Out-of-Pocket Cost COMMunication and Financial Navigation (CostCOM) in Cancer Patients</p>
<p><a href="#">S2013</a> SCHEMA</p>	<p><b>(Peoria, Bloomington, Galesburg, Pekin, Washington)</b> Immune Checkpoint Inhibitor Toxicity: A Prospective Observational Study (I-CHECKIT) (<i>Enrolling to Cohort 2 only: ICI - chemo regimens for NSCLC, SCLC, TNBC, and Gastroesophageal</i>)</p>



<p><a href="#"><u>TP-CA-007 ARIES</u></a></p>	<p>TEMPUS ARIES: A Biobank Registry Platform Study in Oncology (<i>currently enrolling KRAS+ CRC, NSCLC, and Pancreatic cancer pts</i>)</p>
<p><a href="#"><u>URCC-18007</u></a></p>	<p>Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue - <i>at least 2 months out from surgery/tx/radiation</i></p>
<p><a href="#"><u>URCC 19185</u></a></p> <p><a href="#"><u>SCHEMA</u></a></p>	<p><b>(Peoria, Bloomington, Canton, Galesburg, Ottawa, Pekin, Peru, Washington)</b> Multicenter Randomized Controlled Trial Comparing Brief Behavioral Therapy for Cancer Related Insomnia (BBT-CI) and Healthy Eating Education Learning (HEAL)</p>
<p><a href="#"><u>URCC 21038</u></a></p> <p><a href="#"><u>SCHEMA</u></a></p>	<p><b>(Peoria, Bloomington, Galesburg, Pekin, Washington)</b> Disparities in Results of ImmuneCheckpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated With anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting (<i>limited enrollment remaining for caucasian pts - contact CRC to confirm availability</i>)</p>
<p><a href="#"><u>URCC 22063</u></a></p> <p><a href="#"><u>SCHEMA</u></a></p>	<p>Longitudinal Observational Trial to Uncover Subtypes of Cancer Cachexia</p>
<p><a href="#"><u>WF-1901</u></a></p> <p><a href="#"><u>SCHEMA</u></a></p>	<p>Internet-delivered Management of Pain Among Cancer Treatment Survivors (IMPACTS)</p>



# MASTER TRIAL LIST

JANUARY 2025



## PANCREATIC

Navigator - Carrie x3621

<p><a href="#"><u>A022106 - JIT</u></a></p>	<p>Phase II/III Second-Line NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM)</p>
<p><a href="#"><u>EA2192</u></a></p> <p><a href="#">SCHEMA</a></p>	<p>A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation (APOLLO)</p>
<p><a href="#"><u>EAY191 (ComboMATCH) - A3</u></a></p> <p><a href="#">SCHEMA</a></p>	<p>Palbociclib and Binimetinib in RAS-Mutant Cancers: A ComboMATCH Treatment Trial <i>(cohorts for pancreatic cancer and other RAS mutant tumors are temporarily closed)</i></p>
<p><a href="#"><u>S2001</u></a></p> <p><a href="#">SCHEMA</a></p>	<p>Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients With Germline BRCA1 or BRCA2 Mutations</p>
<p><a href="#"><u>S2104 - JIT Trial</u></a></p>	<p>Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors</p>
<p><a href="#"><u>TP-CA-007 ARIES</u></a></p>	<p>TEMPUS ARIES: A Biobank Registry Platform Study in Oncology <i>(currently enrolling KRAS+ CRC, NSCLC, and Pancreatic cancer pts)</i></p>

**PROSTATE**

Navigator - Carrie x3621

**ADJUVANT**

<p><b><u>GU008</u></b></p> <p>SCHEMA</p>	<p><b>(RT at Glen Oak)</b> Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE): <i>Intensifying Treatment for Node Positive Prostate Cancer by Varying the Hormonal Therapy</i></p>
<p><b><u>GU009</u></b></p> <p>SCHEMA</p>	<p><b>(RT at Glen Oak and Rt 91)</b> Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (<b>PREDICT-RT*</b>) (<i>intensification cohort (groups 3 and 4) closed to accrual</i>)</p>
<p><b><u>GU010</u></b></p> <p>SCHEMA</p>	<p><b>(RT at Glen Oak)</b> Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (<b>GUIDANCE</b>) (<i>intensification cohort (groups 3 and 4) closed to accrual</i>)</p>
<p><b><u>GU013</u></b></p> <p>SCHEMA</p>	<p><b>(RT at Glen Oak)</b> The Phase III 'High Five Trial' Five Fraction Radiation for High-Risk Prostate Cancer</p>
<p><b>METASTATIC</b></p>	
<p><b><u>A032102</u></b></p> <p>SCHEMA</p>	<p>PREcision Diagnostics in Prostate Cancer Treatment (PREDICT)</p>
<p><b>MK5684-004</b></p>	<p><b>(Peoria, Bloomington, Galesburg, Pekin, Peru, Ottawa, Washington)</b> A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA)</p>

**S2312**

SCHEMA

A Phase III Study of Cabazitaxel With or Without Carboplatin in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC), Stratified by Aggressive Variant Signature

# MASTER TRIAL LIST

JANUARY 2025



## RENAL CELL

Navigator - Carrie x3621

<p><a href="#"><u>EA8211</u></a></p> <p><a href="#">SCHEMA</a></p>	<p><b>(RT at Rt 91, Glen Oak)</b> Phase III Randomized Trial of Stereotactic Ablative Radiotherapy (SAbR) for Oligometastatic Advanced Renal Carcinoma (SOAR)</p>
<p><a href="#"><u>S2200</u></a></p> <p><a href="#">SCHEMA</a></p>	<p>A Phase II Randomized Trial of Cabozantinib (NSC #761968) With or Without Atezolizumab (NSC #783608) in Patients With Advanced Papillary Renal Cell Carcinoma (PAPMET2)</p>

# MASTER TRIAL LIST

JANUARY 2025

MENU

## RADIATION TRIALS

Navigator - Jessica x3615

BRAIN	
<a href="#"><u>BN011</u></a>	<b>(RT at SJMC, Glen Oak)</b> A Phase III Trial of Gleostine® (Lomustine)-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients With Methylated MGMT Promoter Glioblastoma
BRAIN METS	
<a href="#"><u>BN010</u></a>	<b>(RT at Glen Oak)</b> A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma (currently enrolling to phase II non-surgical cohort)
<a href="#"><u>BN012</u></a>	<b>(RT credentialing pending)</b> A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients with Resectable Brain Metastases
<a href="#"><u>CCTG CE.7</u></a>	<b>(Glen Oak)-</b> A Phase III Trial of Stereotactic Radiosurgery Compared with Whole Brain Radiotherapy (WBRT) for 5-15 Brain Metastases
<a href="#"><u>WF-2201</u></a>	<b>(Glen Oak; Pending at Rt 91)</b> - Hypofractionated Radiotherapy vs Single Fraction Radiosurgery For Brain Metastasis Patients On Immunotherapy ( <b>HYPOGRYPHE</b> )
BREAST	
<a href="#"><u>BR007</u></a>	<b>(Glen Oak, Rt 91, SJMC)</b> Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer
<a href="#"><u>MA.39</u></a>	<b>(Glen Oak)</b> Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
HEAD & NECK	
<a href="#"><u>EA3161</u></a>	<b>Temporarily Closed</b>   <b>(Glen Oak)</b> A Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC

<a href="#"><u>EA3211 - JIT</u></a>	Phase III Randomized Trial of Immunotherapy With or Without Consolidative Radiotherapy for Oligometastatic Head and Neck Squamous Cell Carcinoma
<a href="#"><u>HN009</u></a> <small>SCHEMA</small>	<b>(RT at SJMC)</b> Randomized Phase II/III Trial of Radiation With High-Dose Cisplatin (100 mg/m <sup>2</sup> ) Every Three Weeks Versus Radiation With Low-Dose Weekly Cisplatin (40 mg/m <sup>2</sup> ) for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) ( <i>accrual closed to p16+ oropharyngeal/unknown primary cohort</i> )
<b>NSCLC</b>	
<a href="#"><u>LU008</u></a> <small>SCHEMA</small>	<b>(RT at Glen Oak, SJMC, Rt 91)</b> Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer
<b>PROSTATE</b>	
<a href="#"><u>GU008</u></a> <small>SCHEMA</small>	<b>(RT at Glen Oak)</b> Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE): <i>Intensifying Treatment for Node Positive Prostate Cancer by Varying the Hormonal Therapy</i>
<a href="#"><u>GU009</u></a> <small>SCHEMA</small>	<b>(RT at Glen Oak, Rt 91)</b> Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation ( <b>PREDICT-RT*</b> ) ( <i>intensification cohort (groups 3 and 4) closed to accrual</i> )
<a href="#"><u>GU010</u></a> <small>SCHEMA</small>	<b>(RT at Glen Oak)</b> Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE) ( <i>intensification cohort (groups 3 and 4) closed to accrual</i> )
<a href="#"><u>GU013</u></a> <small>SCHEMA</small>	<b>(RT at Glen Oak)</b> The Phase III 'High Five Trial' Five Fraction Radiation for High-Risk Prostate Cancer
<b>RENAL</b>	
<a href="#"><u>EA8211</u></a> <small>SCHEMA</small>	<b>(RT at Rt 91, Glen Oak)</b> Phase III Randomized Trial of Stereotactic Ablative Radiotherapy (SAbR) for Oligometastatic Advanced Renal Carcinoma (SOAR)
<b>SCLC</b>	

<p><a href="#"><u>NRG CC009</u></a></p> <p><a href="#"><u>SCHEMA</u></a></p>	<p><b>(Glen Oak)</b> - Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell Lung Cancer</p>
<p><a href="#"><u>S1827</u></a></p>	<p><b>(Glen Oak, SJMC)</b> A Randomized Phase III Trial of MRI Surveillance With or Without Prophylactic Cranial Irradiation (PCI) in Small-Cell Lung Cancer</p>





# MASTER TRIAL LIST

JANUARY 2025



## SARCOMA

Navigator - Carrie x3621

**EA7222**

**SCHEMA**

A Randomized Phase III Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas

# MASTER TRIAL LIST

JANUARY 2025



## SMALL CELL LUNG CANCER

Navigator - Ashton x3611

<p><a href="#"><u>CA245-0001</u></a></p>	<p><b>COMING SOON!</b> A Randomized, Double Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012+Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide vs Atezolizumab in Combination With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).</p>
<p><a href="#"><u>NRG CC009</u></a></p> <p><a href="#">SCHEMA</a></p>	<p><b>(RT at Glen Oak)</b> - Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell Lung Cancer</p>
<p><a href="#"><u>S1827</u></a></p>	<p><b>(RT at Glen Oak, SJMC)</b> A Randomized Phase III Trial of MRI Surveillance With or Without Prophylactic Cranial Irradiation (PCI) in Small-Cell Lung Cancer</p>
<p><a href="#"><u>TP-CA-003 (Sculptor)</u></a></p>	<p><b>(Peoria, Blm, Canton, Gburg, Ottawa, Pekin, Peru, Washington)</b> A Tissue and Longitudinal Circulating Tumor DNA (ctDNA) Biomarker Profiling Study of Patients with Small Cell Lung Cancer (SCLC) Using Comprehensive Next-Generation Sequencing (NGS) Assays (TEMPUS)</p>